Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Interest & Investment Income (2016 - 2025)

Sangamo Therapeutics (SGMO) has 14 years of Interest & Investment Income data on record, last reported at $355000.0 in Q3 2025.

  • For Q3 2025, Interest & Investment Income rose 1.43% year-over-year to $355000.0; the TTM value through Sep 2025 reached $3.2 million, up 18.75%, while the annual FY2024 figure was $5.9 million, 47.21% down from the prior year.
  • Interest & Investment Income reached $355000.0 in Q3 2025 per SGMO's latest filing, down from $386000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $3.7 million in Q4 2022 and bottomed at $309000.0 in Q1 2025.
  • Average Interest & Investment Income over 5 years is $1.6 million, with a median of $1.5 million recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: skyrocketed 145.38% in 2023, then plummeted 90.04% in 2024.
  • A 5-year view of Interest & Investment Income shows it stood at $2.3 million in 2021, then surged by 57.45% to $3.7 million in 2022, then tumbled by 59.43% to $1.5 million in 2023, then surged by 45.24% to $2.2 million in 2024, then plummeted by 83.62% to $355000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $355000.0 in Q3 2025, $386000.0 in Q2 2025, and $309000.0 in Q1 2025.